The tweet was deleted by the author.
But we saved everything 🙂.
Esperion Therapeutics announced that it will release its financial results for the first quarter of 2026 on May 7.
This upcoming report is expected to provide insights into the company’s performance and outlook for the year. Investors and analysts will be watching closely for updates on revenue, operating expenses, and progress in its therapy pipeline ahead of the release.
Esperion recently claimed the 88th spot among 300 firms on the Financial Times Americas Fastest Growing Companies 2026 list. The company also presented new data from the CLEAR Outcomes study on NEXLETOL at the ACC Annual Scientific Session 2026. These developments have kept Esperion in focus ahead of its quarterly financial release.